The assessment of the possible role played by the renin-angiotensin system in maintaining arterial hypertension requires an understanding of the mechanisms regulating renin release from the kidney. In addition to intrarenal mechanisms of control, recent investigation stresses the importance of sympathetic influences on the juxtaglomerular cells both in experimental animals and in man. Studies with beta-adrenergic blocking agents, interfering with sympathetic release of renin, and with peptides interfering with the generation or action of angiotensin II, suggest that renin may play MECHANISMS REGULATING RENIN RELEASE FROM THE KIDNEY can be classified' as 1) intrarenal (including both the renal vascular receptor in the afferent arteriole sensitive to local changes in renal perfusion pressure, and the natrioreceptor in the macula densa of the distal tubule sensitive to changes in tubular sodium load or concentration); 2) sympathetic (including the renal nerves as well as catecholamines); and 3) humoral (including sodium, potassium, vasopressin and angiotensin II). Current interpretations of disturbances in renin release have emphasized the classical intrarenal mechanisms, but more recently interest has grown in neural control of renin in hypertension. The present review will concentrate on neural regulation, obviously without implying that the other control mechanisms are of minor importance.
SUMMARY The assessment of the possible role played by the renin-angiotensin system in maintaining arterial hypertension requires an understanding of the mechanisms regulating renin release from the kidney. In addition to intrarenal mechanisms of control, recent investigation stresses the importance of sympathetic influences on the juxtaglomerular cells both in experimental animals and in man. Studies with beta-adrenergic blocking agents, interfering with sympathetic release of renin, and with peptides interfering with the generation or action of angiotensin II, suggest that renin may play MECHANISMS REGULATING RENIN RELEASE FROM THE KIDNEY can be classified' as 1) intrarenal (including both the renal vascular receptor in the afferent arteriole sensitive to local changes in renal perfusion pressure, and the natrioreceptor in the macula densa of the distal tubule sensitive to changes in tubular sodium load or concentration); 2) sympathetic (including the renal nerves as well as catecholamines); and 3) humoral (including sodium, potassium, vasopressin and angiotensin II). Current interpretations of disturbances in renin release have emphasized the classical intrarenal mechanisms, but more recently interest has grown in neural control of renin in hypertension. The present review will concentrate on neural regulation, obviously without implying that the other control mechanisms are of minor importance.
Experimental Findings Sympathoadrenergic Mechanisms of Renin Release
Evidence that the sympatho-adrenergic system can influence renin release has been obtained by several groups of investigators."q In our hands,5 electrical stimulation of the vasomotor center in the pons and medulla produced a sharp some pressor role in a number of cases of hypertension: a major one in the small group of patients with high plasma renin, and possibly a minor one in the large population of patients whose renin is stimulated by treatment with diuretics and vasodilators. On the whole, available evidence suggests that renin disturbances in essential hypertension are rarely primary. It is unlikely, therefore, that renin levels alone can suffice as guideline for treatment of hypertension. A more comprehensive approach should be based on a multifaceted profile, including but not limited to renin. increase in renin release and a fall in renal blood flow to the innervated kidney, while no change in renin release and a slight passive increase in blood flow occurred in the contralateral denervated kidney. In this experiment, therefore, vasoconstriction and renin release were associated. Dissociation of vasomotor and renin-releasing effects of brain stem stimulation could be obtained, however, by intrarenal infusion of a very small amount of an alpha-adrenergic blocker, phenoxybenzamine: in these conditions (fig. 1) brain stem stimulation could not induce any vasomotor change on the injected side, but renin release occurred from both kidneys. A reverse dissociation of the vasomotor and renin-releasing effects of sympathetic stimulation was obtained by injection of a beta-adrenergic blocker, propranolol, which completely abolishes stimulation of renin release while leaving renal vasoconstriction unimpaired.
There is now a large consensus that beta-adrenergic receptors are involved in stimulation of renin release and it has also been postulated that alpha-adrenergic inputs may play an inhibitory role on renin release. Evidence on this topic has been obtained by perfusion experiments of the isolated rat kidney,6' 7 by intra-arterial injection in the dog kidney' and by addition of adrenaline and noradrenaline to the incubation medium of kidney slices.' '" There is also evidence that sympathetic control of renin is centrally organized ( fig. 2 ). Renin release can be increased not only by pontine,' or medullary,, 11 and mesencephalic" stimulation, but also by stimulation of the hypothalamic defense area;"3 and Zehr and Feigl14 have obtained reduction of renin release by stimulation of the so-called sympathoinhibitory area in the anterior hypothalamus. VOL 56, No 5, NOVEMBER 1977 The mechanisms by which various stimuli can release renin have been studied by comparing the response of an innervated kidney to the response of its denervated partner. Different results were however obtained when a much larger dose of furosemide was infused (6 mg/kg): although the innervated kidney released renin in a much greater amount, the denervated kidney also consistently increased its renin output"5 ( fig. 3 , lower left quadrant). Likewise, bilateral reduction of renal perfusion pressure by suprarenal aortic stenosis increased renin release disproportionally more from the innervated than from the denervated kidney, but the denervated organ was also consistently stimulated.1" It can therefore be concluded that of the four stimuli studied, two upright tilting and small doses of diureticseem to activate the juxtaglomerular cells entirely through sympathoadrenergic mechanisms, while the other two large doses of diuretic and aortic stenosis seem to activate both sympathetic and nonsympathetic mechanisms of renin release. Though a crucial proof is lacking, it is likely that the nonsympathetic mechanism activated by large doses of furosemide is the macula densa, and that the one activated by a fall in renal perfusion pressure is the vascular receptor.
Nature of Adrenergic Control of Renin Release
An important, yet unclarified question concerns the nature of the process within the juxtaglomerular cells that is activated by sympathetic and adrenergic stimuli: is it simply accelerated release, in the stricter sense of passage of preformed renin from storage granules into the blood stream, or is it real secretion, in the broader sense of synthesis of new renin within the juxtaglomerular cells? When we studied the time course of the response to stimuli like large doses of furosemide or aortic stenosis ( fig. 3 , lower panels), it was apparent that the neural and the nonneural mechanisms had a different time course, the neural one be- ing immediate, while the nonneural mechanism built up slowly and became more evident toward the end of the stimulation period. The early involvement of the neural mechanism and its subsequent reduced importance may suggest that neural influences, however triggered, might be more responsible for release of renin than for its production. Investigation of such speculation can now be made on the basis of the recent demonstration by several groups17' 18 that an inactive precursor of renin can be found in the kidney and in peripheral plasma. This inactive precursor, also called prorenin or big renin, has a greater molecular weight than active renin, and can be changed into the active enzyme and measured in the laboratory if plasma is incubated at low pH. There is preliminary evidence"9 that adrenergic stimuli (infusion of a j-adrenergic agonist, isoproterenol, or tilting upright), may increase active renin without changing the concentration of total renin: that is, the increase of active renin would occur at the expense of the inactive precursor. Likewise, propranolol is known to reduce active renin but seems to increase the concentration of the inactive enzyme. This suggests, admittedly as a speculation, that one of the roles of the sympathetic control of juxtaglomerular cells may consist in activation of inactive renin. This might provide a further explanation for the apparent paradox observed when studying denervated kidneys, that renal vein concentration is often much lower than concentration in the arterial inflow,20 as if a denervated kidney might turn large amounts of incoming active renin into its inactive precursor. Alternative hypotheses are neural influences on renal extraction of renin or on renal secretion of Anterior Hypothalamus FIGURE 2. Organization of taglomerular cells. 693 VOL 56, No 5, NOVEMBER 1977 inhibitory material. This short-term role of the sympathetic innervation in activation of renin still needs confirmation, and furthermore it does not rule out the possibility that, over a longer period, the sympathetic inflow might influence renin production also.
Reflex Regulation of Renin Release
It is likely that stimuli such as tilting,15 small doses of furosemide'5 and moderate hemorrhage3 that activate the juxtaglomerular cells through entirely neural mechanisms act by way of a reflex mechanism. Several afferent pathways might be involved.2' Identification of the reflex, or possibly of several reflexes, is more difficult: not all paths have been investigated, and the evidence on those that have been investigated is still controversial. Conflicting results have been obtained on the role of sinoaortic afferent fibers, but the weight of evidence is that they play only a minor role." Afferent fibers from low pressure or volume receptors in the cardiopulmonary area, which are known to course in the vagi, are more likely to represent input channels for stimuli, such as the ones we are considering, that decrease central blood volume. In fact Mancia, Romero, and Shepherd22 have found that transient interruption of vagal conduction in the anesthetized dog is followed by a considerable increase in renin release.
The -II release has not gone unchallenged and it has recently been denied that vagotomy causes any increase in renin." We are reinvestigating this controversial issue, and our preliminary data24 ( fig. 4 ) both c9nfirm the observations by Mancia et al. and seem to provide an explanation for the opposite results of other authors. Five minutes after vagotomy a brisk increase in renin release was measured from the innervated kidney whereas an increase was barely perceptible and delayed from the contralateral denervated kidney. The increment in renin release from the innervated kidney was, however, short-lived, and had already disappeared in most animals 15 minutes after vagotomy. This suggests that other reflexes or factors take over and soon compensate for the lack of vagal reflexes. This is a first explanation for the divergent observations of different groups of investigators. Another explanation was provided by experiments in another group of cats. While the animals of figure 4 were moderately fluid-depleted, the animals of the second series were moderately fluid-repleted by saline infusion during the experiment; and this time vagotomy was not followed by any change in renin release either from innervated or denervated kidneys. Vagal receptors appear therefore to exert a reflex role of differing importance in the control of renin depending on various underlying factors, the existing fluid balance being possibly one of these.
Clinical Considerations
Two main sets of tools are available to assess the role of the renin-angiotensin system in man: peptides blocking the renin-angiotensin system, and beta-adrenergic blockers.'5 As this review is mainly concerned with sympathetic control of renin release, and beta-blockers are the only available agents acting on this mechanism, two questions concerning the beta-blockers will be discussed first. Can beta-blocker sensitive renin be equated to neurally-mediated renin? And, does beta-blocker induced hypotension indicate reninmediated hypertension? There is another similarity between neural control of renin release in man and in experimental animals. The similarity concerns reflex control. It has been mentioned above that the balance of current evidence is against thepossibility that the carotid sinus baroreceptor reflex plays a major role in controlling renin in the experimental animal. We have recently investigated this possibility in normal renin hypertensive patients by fitting a large box around their neck and by decreasing or increasing the pressure within the chamber: decreased pressure in the neck chamber increases transmural pressure at the carotid sinus and stimulates the receptors, and vice versa. A decrease in carotid transmural pressure of about 20 mm Hg caused only 100- a very minor response in renin release (measured as the difference in PRA between renal vein plasma and arterial plasma); on the contrary, a very marked increase in renal vein-arterial difference in PRA was observed in the same patients whenever an even smaller decrease in carotid sinus transmural pressure was obtained by head-up tilting.28 This shows that in man neurally-mediated renin release during orthostasis also is induced through receptors other than the carotid sinus ones.
Renin Suppression and Hypotensive Action of Antihypertensive

Drugs
The question to be discussed now is basic to our understanding of the pathophysiology of hypertension, but is also one that is highly controversial, and has divided, and continues to divide, the opinions of investigators and clinicians. The question is whether renin levels, and consequently angiotensin levels, found in most hypertensive patients are such as to exert a pressor action, accounting to a greater or smaller extent for the hypertension. Patients with hypertension are usefully classified, according to the original suggestion of Laragh,29 in the three distinct categories of low, normal, and high plasma renin activity. The role played by renin in maintaining the hypertension has been investigated by means of peptides blocking the reninangiotensin system: the angiotensin antagonist, saralasin, and the converting enzyme inhibitor, SQ 20881. All investigators agree that in high renin patients renin plays a significant pressor role, and that in low renin patients renin is too low to contribute to blood pressure maintenance. 30 33 The difficult cases involve the majority of essential hypertensive patients, those classified as normal renin. In these patients blood pressure is seldom decreased by saralasin,3' but has been more frequently found to be reduced by the converting enzyme inhibitor.3' The fact is that neither of these agents is entirely specific: saralasin is partly agonist, and agonism can partly counterbalance antagonism; the converting enzyme inhibitor also inhibits bradykinin-inactivating enzymes, and might induce hypotension independently of renin. The point is highly controversial, and I shall rather try to keep to a related, but more practical issue; that is, whether suppression of renin by various antihypertensive drugs is the mechanism, or a mechanism of their antihypertensive action, and, on the other hand, whether increase in plasma renin activity by other antihypertensive drugs may be considered as an annoying side effect limiting the hypotensive effectiveness of these drugs.
The first issue concerns the mechanisms of the hypotensive action of beta-blockers, and also of drugs such as alpha-methyldopa and clonidine. The opinion that hypotension induced by beta-blockers results solely or mainly from renin suppression34 has not been supported by recent research. Figure 7 summarizes our own work and shows that the dose-response curves describing the renin-suppressing and the hypotensive actions of propranolol are quite different: almost complete suppression of PRA could be obtained in normal renin patients at plasma propranolol concentrations below 10 ng/ml, that is, at drug levels that just started to yield a hypotensive effect. Hypotension progressively increased with further increases of propranolol 695 VOL 56, No 5, NOVEMBER 1977 PLASMA PROPRANOLOL CONCENTRATION (ng/ml) concentration that, of course, could not produce any further suppression of renin.
It must be noted, however, that our studies were carried out in normal and low renin hypertensive patients. Therefore, our conclusions do not rule out the possibility that high renin hypertensives may be more dependent on renin secretion and that in these patients the hypotensive effect of propranolol may be partly mediated by the reninsuppressing action of the drug.34 Indeed, Shand et al. 35 have presented evidence in favor of a dual mechanism of the hypotensive action of propranolol, one occurring after low doses and at low plasma concentrations of the drug, evident only in high renin patients and possibly due to reninsuppression; the other developing at higher plasma concentrations, evident also in low renin hypertension, and certainly independent of renin suppression, as we have pointed out.
It has also been suggested that drugs such as alphamethyldopa and clonidine would decrease blood pressure through their renin-depressing action, and evidence has been presented suggesting that alpha-methyldopa would not be active in low renin hypertensive patients.36 Recent experiments by our group37 do not support this viewpoint. When 26 hypertensive patients with normal or low renin were subjected to a course of treatment with propranolol (160 mg/day for one week) and then, after a suitable washout period, received variable amounts of alphamethyldopa, propranolol was found much more effective than alpha-methyldopa in suppressing renin, especially in the upright position, but alpha-methyldopa was much more effective than propranolol in lowering blood pressure, especially in the upright position ( fig. 8 ). Furthermore, when alpha-methyldopa was given at different dose levels increased stepwise every week, plasma renin activity was partially depressed by the lowest dose of 500 mg/day and no further decrease was observed when the dose was brought to 1000 mg/day. On the other hand, the hypotensive effect of FIGURE 8 . Reduction of standing values ofplasma renin activity (PRA) and mean arterial blood pressure (MAP) during treatment with propranolol (160 mg/day) and methyldopa (1000-1500 mg/day). The asterisks indicate statistically significant differences between the effects of propranolol and methyldopa (one asterisk, P < 0.05; two asterisks, P < 0.01).
alpha-methyldopa doubled when the dose was doubled from 500 to 1000 mg/day. Once again, as with beta adrenergic blockers, the dose-response curve for the renin-depressive effect of alpha-methyldopa seems to be at the left of the curve for the hypotensive effect.
The next issue is whether a rise in plasma renin activity caused by antihypertensive drugs, and especially by diuretics,38 39 can be considered as a factor limiting the hypotensive activity of the drug. In our experience,'0 when a group of moderately hypertensive patients were treated with the diuretic chlorthalidone, 50-100 mg/day, the hypotensive effect was accompanied by a considerable rise of PRA, both supine and standing.40 Addition of small doses of propranolol, 40 mg/day, to continued diuretic treatment markedly, though not entirely suppressed the rise in PRA and simultaneously caused a further decrease of blood pressure values.'0 More crucial proof that the rise in renin caused by diuretics can indeed have some pressor effect is being sought with current experiments using saralasin (unpublished observations). Preliminary results are presented in figure 9 . In this normal renin hypertensive patient infusion of saralasin at increasing doses from 0.5 to 10 ,ug/kg/min for 60 min caused a pressor response, already very clear at the lowest dose, as at the existing renin levels the agonistic properties of saralasin apparently overcame the antagonistic ones. After two weeks of chlorthalidone 50 mg daily, PRA had clearly risen. Infusion of saralasin had now a slight hypotensive rather than hypertensive effect. This means that the diuretic-induced rise in renin potentiated the antagonistic action of saralasin and overcame its agonistic action.
Conclusions
There is evidence that renin may play some pressor role in a number of cases of hypertension: certainly in the small group of those patients presenting themselves with high plasma renin; possibly in the large population of patients whose renin is stimulated by treatment with diuretics and vasodilators. While the pressor role of renin in high renin patients may be conspicuous, that occurring during treatment with diuretics is mild and can simply blunt but seldom obscure the hypotensive action of the drug. Renin rise during pressure in a patient with essential hypertension before (left) and after 2 weeks therapy with chlorthalidone (50 mg/day). Plasma renin activity, on lying (L) and standing (S), before (left) and after (right) chlorthalidone is also indicated (from unpublished observations).
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chronic diuretic therapy is not a contraindication to the use of these very important antihypertensive agents, but is at most an indication of the advantages of associating diuretic and beta-blocking agents together. The observation that plasma renin in normal subjects and in hypertensive patients is commonly influenced by sympathetic stimuli,25 and that most of the spontaneous or druginduced disturbances of renin in hypertension can be 2 40 modified by beta-blockers, suggests that renin disturbances in essential hypertension are rarely primary, and that they are rather markers of other imbalances, probably in sympathetic activity. The suggestion that hypertensive patients be managed according to their renin profile29 has undoubtedly played an invaluable stimulating role in recent years. In particular the importance of the pathophysiological approach to treatment has been underlined and the dangers of translating the trial and error approach profitably followed for years into a philosophy have been made obvious. However, the conclusion that plasma renin is more a marker than a causative factor of hypertension makes renin alone an inadequate guideline for the pathophysiological understanding and treatment of hypertension. In our present state of knowledge, renin profiles are little more than graffiti representing the pathophysiology of the hypertensive patient: other associated measurements are needed before we obtain at least a bas-relief profile to guide choice of therapeutic treatment. A sufficiently precise marker of the state of sympathetic activity associated with a test of sympathetic withdrawal and a measure of body fluid volumes associated with a test of volume reduction might be usefully added to plasma renin measurements and to the test of the pressor role of renin by peptide blockers. Most of the available antihypertensive drugs act on sympathetic activity, fluid volume, or renin, and this multifaceted profile would cover all these various therapeutic actions. While the final aim in treating such a widespread disease as arterial hypertension is obviously that of reducing diagnostic tests to a minimum, advantages cannot be reasonably expected from the pathophysiological approach unless selected groups of patients undergo in depth testing to provide more rational guidelines for the wider population of patients. and physiological implications. Circ Res 36, 37 
